Drug Trial Radar · NCT00337727
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
Last checked: Nov 19, 2026Latest source record: Jun 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
848
Actual
Start
Jan 1, 2007
Primary completion
Oct 28, 2008
Study completion Nov 19, 2008
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 16, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC). Patients receiving more then one cycle of chemotherapy may opt to participate in an optional second cycle during which the patient will receive the same antiemetic regimen as cycle 1, except that an IV formulation of aprepitant will be given in place of the oral formulation on study day one. Study drug administration on subsequent days will be given orally as in cycle 1.
Conditions
- Chemotherapy-Induced Nausea and Vomiting
Interventions
aprepitantDrug
aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
Comparator: ondansetronDrug
Ondansetron 8 mg capsule Three day treatment period.
Comparator: dexamethasoneDrug
dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
Comparator: fosaprepitant dimeglumineDrug
fosaprepitant dimeglumine 115 mg
Comparator; Placebo (unspecified)Drug
dexamethasone 12mg Pbo tablets.
Comparator; Placebo (unspecified)Drug
Aprepitant 80 mg \& 125 mg Pbo capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Who Reported No VomitingTime frame: Overall phase (0-120 hours post initiation of MEC) in Cycle 1.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.